Skip to content
This GLP
← Research
Formats

Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes

Four weeks at 0.25 mg, then a step every four weeks to 1.7 or 2.4 mg. What changes with a compounded vial is not the milligrams — it is who measures them.

Glenn Torres7 min read
The labeled ladder — four weeks on every rung0.25wk 1–40.5wk 5–81wk 9–121.7wk 13–162.4wk 17+Milligrams weekly. No compounded product carries this label.

The short answer is 0.25 mg once weekly for the first four weeks. The longer answer has three parts. The number comes from the approved product’s label. No compounded vial has a label of its own. And the step that goes wrong is not choosing the dose. It is drawing it.

What the labeled ladder actually is

The prescribing information for the approved injection sets a fixed escalation schedule and tells prescribers to titrate every four weeks [5]. Every rung below is four weeks long.

Recommended starting dosage and escalation, approved semaglutide injection.
WeeksWeekly doseWhat this rung is for
1–40.25 mgStarting dosage. Not a treatment dose.
5–80.5 mgFirst escalation step.
9–121 mgSecond escalation step.
13–161.7 mgThird step — also a valid maintenance dose.
17 and onward1.7 mg or 2.4 mgMaintenance for weight reduction.
Recommended starting dosage and escalation, approved semaglutide injection. FDA prescribing information via DailyMed, read September 2026

Two provisions matter more than the numbers. If a dose is not tolerated, the label says to consider delaying escalation by four weeks rather than pushing on. Miss two or more consecutive weekly doses and escalation restarts at a lower dose. You do not resume where you left off. That second rule catches people who travel, run out, or wait on a refill.

Why it starts so low

0.25 mg is not a weight-loss dose. It exists to get the gut used to the drug — the reasoning behind every published ladder. The STEP 1 to 3 trials pooled their gastrointestinal events at 2.4 mg. Nausea ran 43.9% against 16.1% on placebo. Vomiting ran 24.5% against 6.3%. Diarrhea ran 29.7% against 15.9% [2]. Those events clustered during and shortly after escalation, and 98.1% were mild to moderate.

43.9%

had nausea on 2.4 mg (16.1% on placebo)

STEP 1–3 pooled

98.1%

of gut side effects were mild or moderate

STEP 1–3 pooled

4.3%

stopped permanently because of them

STEP 1–3 pooled

<1 pt

of the weight loss was explained by them

mediation analysis

What changes when the product is compounded

The milligrams do not change. The delivery does. An approved product arrives as a pen, with the dose selected for you. A compounded product typically arrives as a vial with syringes. The arithmetic moves to your kitchen table.

A poison-control case series describes what that costs. Of three cases of compounded semaglutide administration errors, two were ten-fold overdoses. All three patients had nausea, vomiting and abdominal pain lasting days. One received a vial and syringes with no pharmacist counseling. One reported dosing in milliliters and units rather than milligrams [3]. The authors’ conclusion is about the format. Vials do not carry the safety features of a prefilled pen. Syringes not intended for semaglutide make the unit ambiguous.

Is the compounded version riskier?

One study read the FDA’s adverse event database from 2018 to 2024. It compared 707 reports involving compounded products against 81,078 GLP-1 reports in total [4]. Compounded products carried higher reporting odds on four counts. Preparation errors: ROR 48.92 (95% CI 12.63 to 189.6). Contamination: 19.00 (4.24 to 85.03). Compounding or manufacturing issues: 8.51 (5.17 to 14.0). Hospitalization: 2.35 (1.94 to 2.83).

The same study found lower reporting odds for administration errors (0.29) and dosing errors (0.24). That runs against the case-series picture. It is worth stating rather than hiding. Reporting odds ratios measure what gets reported, not what happens. A disproportionality signal is not an incidence rate. Read the direction and the intervals, not the point estimates.

So what should you actually do in week one

Start at the dose your prescriber wrote, which for a first course is almost always 0.25 mg weekly. Read the concentration printed on your vial and have whoever dispensed it confirm the mark on the syringe before the first injection. Hold each rung four weeks. If a rung is rough, the label advises staying there another four weeks rather than climbing. Miss two weeks in a row and expect to step back down. What happens at the top of the ladder is a separate question, covered in how deep a published dose ladder goes.

This guide will not tell you which concentration to buy. It will not convert milligrams to units for a specific vial. That calculation has a wrong answer, and the wrong answer sends people to hospital. The person dispensing your medication should do it with you.

Frequently asked

What is the starting dose of compounded semaglutide?
Almost always 0.25 mg once weekly for four weeks, following the approved product's labeled schedule. No compounded semaglutide has an FDA-approved label of its own, so that ladder is borrowed by convention rather than required.
How many units is 0.25 mg?
There is no single answer. It depends on the concentration of your vial — the same 0.25 mg sits at a different mark at 2.5 mg/mL than at 5 mg/mL. Have the pharmacy that dispensed it confirm the mark before your first injection.
How long before I move up to the next dose?
Four weeks on each rung: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then maintenance at 1.7 or 2.4 mg from week 17. If a dose is not tolerated, the label advises delaying escalation by another four weeks.
What if I miss a couple of weeks?
If two or more consecutive weekly doses are missed, the label says to reinitiate escalation at a lower dose rather than resume where you stopped.
Is compounded semaglutide more dangerous than the branded product?
Adverse event reports show higher reporting odds of preparation errors, contamination and hospitalization for compounded products, though lower odds of dosing errors. These are disproportionality signals in a voluntary reporting system, not incidence rates.

Sources

  1. [1] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. PMID 33567185
  2. [2] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. PMID 34514682
  3. [3] Lambson JE, Flegal SC, Johnson AR (2023). Administration errors of compounded semaglutide reported to a poison control center-Case series Journal of the American Pharmacists Association. PMID 37392810
  4. [4] McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. PMID 40285721
  5. [5] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 1 DailyMed, U.S. National Library of Medicine. Source

Where to get it

Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

Compare providers →

More in Formats